Skip to search formSkip to main contentSkip to account menu

Seliciclib

An orally available small molecule and cyclin-dependent kinase (CDK) inhibitor with potential apoptotic and antineoplastic activity. CDKs, serine… 
National Institutes of Health

Related topics

Related topics

9 relations
CYC 202Cyclin-Dependent KinasesGene Expression RegulationNCIt Antineoplastic Agent Terminology

Broader (1)

roscovitine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pharmacological Management of Cushing ’ s Disease
  • 2017
  • Corpus ID: 21732895
The role of pharmacological management of Cushing’s disease is dual, to prepare patients before any surgical intervention and to… 
2013
2013
Seliciclib Inhibits Renal Hypertrophy but Not Fibrosis in the Rat following Subtotal Nephrectomy
Background: 5/6 subtotal nephrectomy (SNx) is a non-immune stimulus used to induce renal fibrosis. The ability of seliciclib, a… 
2013
2013
The dosage regimen of sapacitabine and seliciclib
本発明の第１の態様は、対象における増殖性障害を治療する方法であって、治療有効量の（ｉ）サパシタビン又はその代謝産物及び（ii… 
2009
2009
Abstract #3863: Derivatives of seliciclib with improved potency both in vitro and in vivo as novel cyclin dependent kinase (CDK) inhibitors
Seliciclib (CYC202, R-roscovitine) is a tri-substituted purine inhibitor of CDKs 2, 7 and 9 that is currently in Phase II… 
2007
2007
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas
Despite recent improvements in treatment, a significant fraction of patients with diffuse large B-cell lymphoma (DLBCL) still… 
2007
2007
Liver effects of cyclin-dependent kinase inhibitor seliciclib. Relations with circadian pharmacokinetics and liver clock disruption.
A106 Background: The therapeutic activity of Seliciclib, a cyclin-dependent kinase (CDK) inhibitor, involves the induction of… 
2007
2007
Cyclin-Dependent Kinase Inhibitors Sensitize Tumor Cells to Nutlin-Induced Apoptosis : a Potent Drug Combination Chit
Current chemotherapy focuses on the use of genotoxic drugs that may induce general DNA damage in cancer cells but also high… 
2006
2006
Cyclin-Dependent Kinase Inhibitor Seliciclib Shows In Vitro Activity in Diffuse Large B Cell Lymphomas.
Background. Despite recent improvements in treatment, a significant fraction of patients with diffuse large B cell lymphoma… 
2006
2006
Inflammation: Helping hand for halting inflammation
10.1038/nrd2185 The defence mechanisms that enable our immune cells to battle pathogens are potentially deleterious to normal… 
2005
2005
Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)